Detect relapse sooner with Foresight CLARITY, a highly sensitive and extremely advanced ctDNA detection technology.

See relapses that others miss

See relapses that others miss.

Foresight’s peer-reviewed and proprietary PhasED-Seq technology is an ultra-sensitive, liquid-biopsy based test that detects MRD from cirtculating tumor DNA (ctDNA). PhasED-Seq powers our Foresight CLARITY MRD test and has been validated in thousands of real-world samples from patients with B-cell malignancies, lung cancer, and breast cancer.1,2,3

View PhasED-Seq Publications


Learn about Foresight CLARITY


Detect disease when it matters most.

Disease-free or MRD? Transform a patient’s health journey by knowing 200 days earlier than clinical relapse[1].



Foresight Diagnostics detection method comparison Foresight Diagnostics detection method comparison

See levels below 1 part per million

By tracking unique genomic differences between cancer and healthy cells with unparalleled accuracy, Foresight CLARITY can detect ctDNA levels below 1 part per million, which is up to 100 times lower than other methods.

Current detection methods vs Foresight Diagnostics detection method comparison diagram
Meet our team right arrow Partner with us right arrow

1 Kurtz, D.M., Soo, J., Co Ting Keh, L. et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol 39, 1537–1547 (2021)

2 Roschewski, M., Kurtz, D.M., Westin, J. et al. MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design. Blood (2022) 140 (Supplement 1): 785–786.

3 Isbell, J.M., Li, B.T., Eichholtz, J.E. et al. Ultrasensitive ctDNA MRD Monitoring in early stage lung cancer with PhasED-Seq. Poster, AACR 2023 Annual Meeting